AAU
0.005
66.7%
VML
0.002
-33.3%
IFG
0.008
60%
FCT
0.013
-23.5%
BLZ
0.003
50%
CXU
0.007
-22.2%
CVR
0.24
45.5%
AW1
0.04
-21.6%
HIO
0.023
43.8%
AYT
0.004
-20%
SHN
0.01
42.9%
BYH
0.004
-20%
DTR
0.078
41.8%
EVR
0.004
-20%
DTM
0.004
33.3%
NRX
0.013
-18.8%
WYX
0.027
28.6%
RON
0.16
-17.9%
4DS
0.065
27.5%
PCL
0.01
-16.7%
ROG
0.005
25%
PGY
0.005
-16.7%
TOU
0.02
25%
VEN
0.005
-16.7%
G50
0.155
24%
FML
0.355
-15.5%
RCE
0.355
20.3%
NHE
0.011
-15.4%
FG1
0.03
20%
FGR
0.028
-15.2%
IPT
0.006
20%
AN1
0.006
-14.3%
OLL
0.018
20%
ARV
0.006
-14.3%
RC1
0.006
20%
GLL
0.006
-14.3%
WBE
0.006
20%
HMD
0.012
-14.3%
AZ9
0.031
19.2%
MKL
0.012
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

HITIQ (ASX:HIQ) receives US Patent approval linked to its Nexus™ concussion management technology

HITIQ (ASX:HIQ) has received approval for a US Patent relating to impact processing technology for its Nexus™ technology.

  • The Company provides software and hardware designed to monitor concussive impacts in the brain incurred by sports players
  • This technology enables data driven decisions for thousands of professional and amateur sports players who experience brain impacts, empowers clinicians who care for the brains of these players
  • HITIQ technology now supported by foundational IP protection in key jurisdiction
  • Data categorization is a key aspect of IP related to field performance of technology

HITIQ Chief Executive, Mike Vegar, said: “Receiving approval for our maiden US patent signals our technology as globally relevant and helps forge a pathway into the US, our key commercial jurisdiction. This approval ensures our ability to protect an integral component of our product and technology in the largest addressable market within our product category. We will continue to build our global patent portfolio with our pipeline of IP activity to gradually emerge.”

Read the ASX announcement here